Mechanisms by Which Ranolazine Terminates Paroxysmal but Not Persistent Atrial Fibrillation.

Animals Atrial Fibrillation / drug therapy Body Surface Potential Mapping Disease Models, Animal Heart Conduction System / drug effects Heart Rate / drug effects Male Ranolazine / therapeutic use Sheep Sodium Channel Blockers / therapeutic use
antiarrhythmic drugs atrial fibrillation catheter ablation dofetilide dominant frequency ranolazine rotors

Journal

Circulation. Arrhythmia and electrophysiology
ISSN: 1941-3084
Titre abrégé: Circ Arrhythm Electrophysiol
Pays: United States
ID NLM: 101474365

Informations de publication

Date de publication:
10 2019
Historique:
entrez: 10 10 2019
pubmed: 9 10 2019
medline: 12 5 2020
Statut: ppublish

Résumé

Ranolazine inhibits Na PxAF was maintained during acute stretch (N=8), and PsAF was induced by long-term atrial tachypacing (N=9). Isolated, Langendorff-perfused sheep hearts were optically mapped. In PxAF ranolazine (10 μmol/L) reduced dominant frequency from 8.3±0.4 to 6.2±0.5 Hz ( PxAF and PsAF respond differently to ranolazine. Cardioversion in the former can be attributed partly to decreased dominant frequency and singularity point density, and prolongation of AFCL. In the latter, increased dispersion of AFCL and likely vortex shedding contributes to rotor formation, compensating for any rotor loss, and may underlie the inefficacy of ranolazine to terminate PsAF.

Sections du résumé

BACKGROUND
Ranolazine inhibits Na
METHODS
PxAF was maintained during acute stretch (N=8), and PsAF was induced by long-term atrial tachypacing (N=9). Isolated, Langendorff-perfused sheep hearts were optically mapped.
RESULTS
In PxAF ranolazine (10 μmol/L) reduced dominant frequency from 8.3±0.4 to 6.2±0.5 Hz (
CONCLUSIONS
PxAF and PsAF respond differently to ranolazine. Cardioversion in the former can be attributed partly to decreased dominant frequency and singularity point density, and prolongation of AFCL. In the latter, increased dispersion of AFCL and likely vortex shedding contributes to rotor formation, compensating for any rotor loss, and may underlie the inefficacy of ranolazine to terminate PsAF.

Identifiants

DOI: 10.1161/CIRCEP.117.005557 PMID: 31594392 PMC: PMC6788778
pubmed: 31594392
doi: 10.1161/CIRCEP.117.005557
pmc: PMC6788778
mid: NIHMS1538964
doi:

Substances chimiques

Sodium Channel Blockers 0
Ranolazine A6IEZ5M406

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e005557

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL118304
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL122352
Pays : United States

Références

Pharmacol Rev. 2010 Dec;62(4):760-81
pubmed: 21079043
Am J Physiol Heart Circ Physiol. 2011 Oct;301(4):H1606-14
pubmed: 21821778
Circ Res. 2014 Apr 25;114(9):1483-99
pubmed: 24763466
J Physiol. 2013 Sep 1;591(17):4087-97
pubmed: 23732646
Circ Arrhythm Electrophysiol. 2012 Dec;5(6):1160-7
pubmed: 23051840
J Am Coll Cardiol. 2010 May 25;55(21):2330-42
pubmed: 20488304
Circ Arrhythm Electrophysiol. 2012 Jun 1;5(3):561-70
pubmed: 22467674
Biophys J. 2005 Jun;88(6):3806-21
pubmed: 15792974
JACC Basic Transl Sci. 2016 Apr;1(3):143-154
pubmed: 27525318
Cardiovasc Res. 2011 Mar 1;89(4):862-9
pubmed: 21233253
J Cardiovasc Electrophysiol. 1999 Feb;10(2):178-93
pubmed: 10090222
Circulation. 1997 Dec 2;96(11):4027-35
pubmed: 9403628
J Cardiovasc Electrophysiol. 2012 May;23(5):447-54
pubmed: 22537106
Heart Rhythm. 2008 Jun;5(6 Suppl):S1-6
pubmed: 18456193
Trends Cardiovasc Med. 2017 Jan;27(1):14-25
pubmed: 27520496
FASEB J. 2018 Apr;32(4):1778-1793
pubmed: 29162702
Circulation. 2007 Sep 25;116(13):1449-57
pubmed: 17785620
Br J Pharmacol. 2017 Aug;174(15):2576-2590
pubmed: 28542844
Circulation. 2004 Aug 24;110(8):904-10
pubmed: 15302796
Circulation. 2000 Jul 11;102(2):260-7
pubmed: 10889140
Circ Arrhythm Electrophysiol. 2013 Apr;6(2):334-41
pubmed: 23512204
Lancet. 2010 Apr 3;375(9721):1212-23
pubmed: 20334907
Biophys J. 1996 Mar;70(3):1105-11
pubmed: 8785270
Circulation. 2004 Jan 27;109(3):363-8
pubmed: 14732752
J Cardiovasc Electrophysiol. 2006 Jun;17(6):648-54
pubmed: 16836716
Br J Pharmacol. 2004 Aug;142(8):1300-8
pubmed: 15277312
Circ Res. 2013 Mar 1;112(5):849-62
pubmed: 23449547
Circ Res. 1992 Aug;71(2):271-87
pubmed: 1628386
Eur Heart J. 2014 Feb;35(8):501-7
pubmed: 24135832
Europace. 2013 May;15(5):761-9
pubmed: 23376977
Circ Heart Fail. 2014 Jul;7(4):627-33
pubmed: 24874201
Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4291-6
pubmed: 23440193
Physiol Rev. 2011 Jan;91(1):265-325
pubmed: 21248168
Circ Res. 2011 Oct 14;109(9):1055-66
pubmed: 21921263
J Am Coll Cardiol. 1997 Dec;30(7):1785-92
pubmed: 9385908
Biophys J. 2010 May 19;98(10):2091-101
pubmed: 20483316
J Cardiovasc Electrophysiol. 2009 Jul;20(7):796-802
pubmed: 19298570
J Am Coll Cardiol. 2017 Dec 12;70(23):2893-2905
pubmed: 29216985
Circulation. 2014 Apr 8;129(14):1472-82
pubmed: 24463369
Circulation. 1995 Oct 1;92(7):1954-68
pubmed: 7671380
Europace. 2014 Nov;16 Suppl 4:iv3-iv10
pubmed: 25362167

Auteurs

Rafael J Ramirez (RJ)

Center for Arrhythmia Research, Department of Internal Medicine-Cardiology, University of Michigan, Ann Arbor (R.J.R., Y.T., R.P.M., D.F.-R., S.R.E., S.M., O.B., J.J., S.V.P.).

Yoshio Takemoto (Y)

Center for Arrhythmia Research, Department of Internal Medicine-Cardiology, University of Michigan, Ann Arbor (R.J.R., Y.T., R.P.M., D.F.-R., S.R.E., S.M., O.B., J.J., S.V.P.).

Raphaël P Martins (RP)

Center for Arrhythmia Research, Department of Internal Medicine-Cardiology, University of Michigan, Ann Arbor (R.J.R., Y.T., R.P.M., D.F.-R., S.R.E., S.M., O.B., J.J., S.V.P.).

David Filgueiras-Rama (D)

Center for Arrhythmia Research, Department of Internal Medicine-Cardiology, University of Michigan, Ann Arbor (R.J.R., Y.T., R.P.M., D.F.-R., S.R.E., S.M., O.B., J.J., S.V.P.).
Fundación Centro Nacional de Investigaciones Cardiovasculares, Carlos III (CNIC; D.F.-R., J.J.).
Centros de Investigación Biomédica en Red (CIBER) for Cardiovascular Diseases, Madrid, Spain (D.F.-R., J.J.).

Steven R Ennis (SR)

Center for Arrhythmia Research, Department of Internal Medicine-Cardiology, University of Michigan, Ann Arbor (R.J.R., Y.T., R.P.M., D.F.-R., S.R.E., S.M., O.B., J.J., S.V.P.).

Sergey Mironov (S)

Center for Arrhythmia Research, Department of Internal Medicine-Cardiology, University of Michigan, Ann Arbor (R.J.R., Y.T., R.P.M., D.F.-R., S.R.E., S.M., O.B., J.J., S.V.P.).

Sandesh Bhushal (S)

Department of Engineering, Norfolk State University, VA (S.B., M.D.).

Makarand Deo (M)

Department of Engineering, Norfolk State University, VA (S.B., M.D.).

Sridharan Rajamani (S)

Gilead Sciences, Foster City, CA (S.R., L.B.).
Currently: Amgen Inc, San Francisco, CA (S.R.).

Omer Berenfeld (O)

Center for Arrhythmia Research, Department of Internal Medicine-Cardiology, University of Michigan, Ann Arbor (R.J.R., Y.T., R.P.M., D.F.-R., S.R.E., S.M., O.B., J.J., S.V.P.).

Luiz Belardinelli (L)

Gilead Sciences, Foster City, CA (S.R., L.B.).

José Jalife (J)

Center for Arrhythmia Research, Department of Internal Medicine-Cardiology, University of Michigan, Ann Arbor (R.J.R., Y.T., R.P.M., D.F.-R., S.R.E., S.M., O.B., J.J., S.V.P.).
Fundación Centro Nacional de Investigaciones Cardiovasculares, Carlos III (CNIC; D.F.-R., J.J.).
Centros de Investigación Biomédica en Red (CIBER) for Cardiovascular Diseases, Madrid, Spain (D.F.-R., J.J.).

Sandeep V Pandit (SV)

Center for Arrhythmia Research, Department of Internal Medicine-Cardiology, University of Michigan, Ann Arbor (R.J.R., Y.T., R.P.M., D.F.-R., S.R.E., S.M., O.B., J.J., S.V.P.).

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Mechanisms by Which Ranolazine Terminates...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Troubles du rythme cardiaque › Fibrillation auriculaire › Mechanisms by Which Ranolazine Terminates...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Électrodiagnostic › Électrocardiographie › Vectocardiographie › Cartographie du potentiel de surface corporelle › Mechanisms by Which Ranolazine Terminates...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Mechanisms by Which Ranolazine Terminates...
questionsmedicales.fr › Système cardiovasculaire › Coeur › Système de conduction du coeur › Mechanisms by Which Ranolazine Terminates...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques cardiovasculaires › Hémodynamique › Rythme cardiaque › Mechanisms by Which Ranolazine Terminates...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pipérazines › Ranolazine › Mechanisms by Which Ranolazine Terminates...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Artiodactyla › Ruminants › Ovis › Mechanisms by Which Ranolazine Terminates...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents cardiovasculaires › Bloqueurs de canaux sodiques › Mechanisms by Which Ranolazine Terminates...